News and Trends 21 Jun 2022 Elektrofi raises $40M to develop drug formulation and delivery pipeline Boston, U.S.-based biotech Elektrofi has completed a $40 million series B funding round. The company, which focuses on drug formulation and delivery, will use a portion of the proceeds to establish a centralized manufacturing line to support multiple upcoming clinical trials. The company also aims to double staff numbers over the next 12-18 months to […] June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 New agreement could lead to first African-owned COVID-19 vaccine A year after the creation of the mRNA Vaccine Technology Transfer Hub, two biotech companies – Afrigen Biologics and the Univercells Group – are set to work together. The agreement intends to pave the way for the development of the first African-owned COVID-19 vaccine. The collaboration will focus on the development of a novel mRNA […] June 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Aussie uni develops new 3D printing solution for stem cell manufacturing Researchers at the University of Technology Sydney (UTS), Australia, have developed a 3D printed system for harvesting stem cells from bioreactors. The scientists said this could lead to high quality, wide-scale production of stem cells in Australia at a lower cost. Stem cells offer great promise in the treatment of many diseases and injuries, from […] June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2022 Investment in Hyperthermics’ process to turn biowaste into energy and proteins Farvatn Private Equity and Måsøval Eiendom have invested in the Norwegian biotechnology company Hyperthermics AS. Through the investment, Farvatn and Måsøval now hold approximately 11% of the shares in Hyperthermics. Hyperthermics’ technology is based on hyperthermophilic bacteria, which degrade biomass, resulting in biogas and protein production. The high temperatures involved – 80ºC – speed up […] June 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2022 Boost for dementia gene-based therapies The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) have announced a collaboration to accelerate the clinical development of adeno-associated virus (AAV) based gene therapies for dementia. Since 2015, dementia has been one of the leading causes of mortality in the UK. While new and improved treatments for […] June 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2022Beyond Biotech podcast 1: Forbion, OMass, PharNext It’s the first official Beyond Biotech podcast! And this week, we have three interviews. We talked with Ros Deegan, CEO of OMass; David Solomon, CEO of PharNext; and two people from Forbion, Sander Slootweg, managing partner, and Dirk Mertens, general partner. Forbion European life sciences venture capital firm Forbion, has announced the first €470M ($500M) […] June 17, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Gimv creates new fund for life science companies European investment company Gimv has launched its fifth investment platform with a focus on venture capital investments in innovative life sciences companies. Gimv said after growth in its existing healthcare platform, a dedicated life sciences platform will strengthen its role in the international life science venture capital ecosystem. The company added its key investment focus […] June 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Molecular farming company Moolec Science joins with LightJump to list on Nasdaq Moolec Science Ltd., a science-based food ingredient company, and LightJump Acquisition Corp., a publicly traded special purpose acquisition company, have agreed to a business combination that would result in Moolec Science SA, a newly-created affiliate of Moolec incorporated in Luxembourg, becoming a publicly listed company. Moolec and U.S.-based LightJump will ultimately become wholly-owned subsidiaries of […] June 16, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Clean and green: Unilever and Geno launch $120m palm oil alternatives venture Unilever and U.S. biotech company Genomatica (Geno) are working on a plan to scale and commercialize alternatives to palm oil and fossil fuel-derived cleansing ingredients. The companies said due to growing demand for sustainably-sourced palm oil, they aim to deliver new responsibly-sourced palm oil alternatives to the market. With $120m jointly invested in the newly-formed […] June 16, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first close of its financing round, raising $10.7 million. It was led by Lifeline Ventures and joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance phase I/II programs in Europe and the U.S., using TILT-123 plus […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Sling Therapeutics emerges with $35M to tackle thyroid eye disease Michigan-based biopharma company Sling Therapeutics, Inc. has launched, with $35 million in series A financing led by TPG’s The Rise Fund. The company is focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The funds support a phase 2b clinical trial evaluating its investigational drug, linsitinib. “We […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2022 Eurocine Vaccines expands portfolio to develop HSV-2 vaccine Swedish company Vaccines AB (Eurocine Vaccines) has entered into a research and collaboration agreement with Redbiotec AG. The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2), based on technologies developed by Swiss biotech company Redbiotec. The agreement covers both an mRNA […] June 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email